Suzhou Inhal Pharma Co., Ltd, a China-based company dedicated to the research and development of inhalation formulations, inhalers, and filling equipment, has reportedly secured over RMB 50 million (USD 6.8 million) in a Series A financing round. The investment round was spearheaded by Shining Capital, marking a significant boost for the company’s growth and development plans.
Strategic Plans Post-Funding
With the new funds, Inhal Pharma is poised to establish a subsidiary in Beijing, a strategic move to expand its operational footprint. The company also plans to advance its lead products into clinical stages, a critical step in bringing innovative inhalation therapies to market. Additionally, Inhal Pharma intends to strengthen the development of novel preparations and devices through strategic partnerships, further solidifying its position in the industry.
Founding and Technological Expertise
Inhal Pharma was founded in June 2020 by Professor Jingxu Zhu, an esteemed academician of the Academy of Science of the Royal Society of Canada and the Canadian Academy of Engineering. The company is distinguished by its advanced technologies, including ultrafine powder preparation and fluidization, ultrafine dry powder drug quantitative repackaging technology (200μg±5%), and low-resistance inhalation flow channel design, development, and verification technology. These innovations position Inhal Pharma at the forefront of inhalation drug delivery solutions.-Fineline Info & Tech
